[Superoxide dismutase (Cu/Zn) in cutaneous application in the treatment of radiation-induced fibrosis].
The aim of the paper consists to select criterias of the therapeutic effect of superoxide-dismutase (PEG-SOD) administrated as an ointment twice a day for 3 months. An original scoring method including qualitative and quantitative data was set up in order to appreciate the importance of the fibrosis and its variations when under local administration of PEG-SOD. Clinical and paraclinical controls were made as T0, T1 (6 weeks), T2 (3 months), T3 (6 months). After 6 months, results enabled us to show PEG-SOD in its galenic form was efficient on radiofibrosis with a 41% score reduction compared to pretreatment score T0, thus an improvement of nearly half of the potential theoretical recovery. The therapeutic efficiency was greater on the most recent fibrosis and there was a chronological order to the different recovery stages. After 6 weeks of administration pains were reduced or stopped; then after 3 months of treatment fibrous texture broke up and softened. An effective reduction of the surface as well as lightened of the pigmentation would not usually start until the 4th month after the start of treatment. PEG-SOD is thus an enzyme the therapeutic interest of which offers interesting prospects. The score which was set up enable a fair evaluation of the intensity and the variations of the treated fibrosis. A prospective study is currently on going in order to research the biological conditions in which the enzyme reacts.
Perdereau
B
B
Laboratoire de radiopathologie clinique, institut Curie, Paris, France.
Campana
F
F
Vilcoq
J R
JR
de la Rochefordière
A
A
Barbaroux
C
C
Fourquet
A
A
Magdelenat
H
H
D000279:Administration, Cutaneous; D001943:Breast Neoplasms / Q000532:radiotherapy; D004341:Drug Evaluation; D005260:Female; D005355:Fibrosis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D009824:Ointments; D011832:Radiation Injuries / Q000188:drug therapy*; D011878:Radiotherapy / Q000009:adverse effects*; D012867:Skin / Q000473:pathology*; D013482:Superoxide Dismutase / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D009824:Ointments; D013482:Superoxide Dismutase